Vesicar (solifenacin) in the treatment of urinary bladder hyperactivity
Urinary bladder hyperactivity (UBH) is highly prevalent chronic disease. The pharmaceutical market has enough variants of antimuscarinic drugs, nonselective (oxybutynin, tolterodine, trospium chloride, propiverin) and selective (solifenacin, darifenacin), which are used in the treatment of UBH. The article includes the results of many randomized multicentral trials in which efficiency and safety of solifenacin (Vesicar) was evaluated. It was shown that treatment by solifenacin decreases the symptoms of UBH and improves patients quality of life. The main advantages of solifenacin are possibility to change the dosage depending on symptoms severity and simplicity of treatment (once a day). Because of the small number of adverse effects solifenacin (Vesicar) it can be recommended as a “gold standard” of UBH treatment in all patients groups.

Keywords: solifenacin, urgency, detrusor hyperactivity, urinary bladder hyperactivity